Novo Nordisk A/S (NVO) Earnings

Novo Nordisk A/S

NVO · NYSE

Sep 2026upcoming

Next quarter

Reports Nov 4, 2026.

Consensus is $0.80 EPS for Sep 2026 across 5 estimates, ranging $0.74 to $0.86.

NVO Jun 2026

Reported Aug 4, 2026

: 17.07%
: +0.56%

: $0.82
: $0.96
: —
: —

Our read on this quarter has not been written yet. The filed figures and the source documents are above and below.

Symbol: NVO
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: NYSE

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries.

Key Issues

Bullish view

The company remains a major GLP-1 player, and positive semaglutide results in the STEP Young pediatric obesity study support additional patient and indication growth.

Bearish view

The Motley Fool says Novo lost the lead to Eli Lilly, while Morgan Stanley’s bearish case centers on further market-share losses to Lilly and intensifying competitive pressure.

Analyst Consensus

See all

Underperform

13 analysts

$43

Current

—

Low

$47

Average

—

High

Average target implies +8.17% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Abbott LaboratoriesABT · NYSE